EirGenix Inc. (TPEX: 6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
87.40
+0.80 (0.92%)
Nov 20, 2024, 1:30 PM CST
-13.03%
Market Cap 27.45B
Revenue (ttm) 1.17B
Net Income (ttm) -986.69M
Shares Out 305.71M
EPS (ttm) -3.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 353,158
Open 86.90
Previous Close 86.60
Day's Range 86.50 - 88.00
52-Week Range 72.20 - 109.50
Beta 0.61
Analysts n/a
Price Target n/a
Earnings Date Nov 11, 2024

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2023, EirGenix's revenue was 1.02 billion, a decrease of -30.95% compared to the previous year's 1.48 billion. Losses were -915.21 million, 692.1% more than in 2022.

Financial Statements

News

There is no news available yet.